Skip to main content
OpenTrials
Completed

NCT Number: NCT05385783

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depressive Disorder Behavior Behavioral Symptoms Depression Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

CenExel ACMR, Atlanta, Georgia, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- MDD & Healthy Volunteer Participants:

  • Aged between 21 to 65 years, inclusive, at Screening.
  • Has a BMI of 18 to 30 kg/m2, inclusive, at Screening.
  • Is ≥60 kg.
  • Is negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test at Screening and at Day -1.
  • Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Additional Inclusion Criteria - MDD Participants Only:

  • Has a diagnosis of MDD (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-V] of moderate to severe degree), established through a full psychiatric work up, who are otherwise healthy.
  • Has been on a stable dose of antidepressant medication (no more than 50% change) in the last month prior to Screening and has had an inadequate response, as judged by the Investigator.

Exclusion criteria

- MDD & Healthy Volunteer Participants:

  • Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview.
  • Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including [but not limited to], neurological, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder).
  • Diagnosis of hypertension or an arrhythmia.
  • History of hypothyroidism and/or current abnormal thyroid function tests.
  • Clinically relevant abnormal laboratory results.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug.
  • Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.
  • Not fluent in the English language.
  • Has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).
  • Positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibody (anti- HCV) or human immunodeficiency virus I and II (anti-HIV I/II) at Screening.
  • Has participated in a clinical study and has received a medication or a new chemical entity within 3 months prior to dosing of current study medication.
  • Is taking or has taken any drugs known to inhibit monoamine oxidase within 28 days prior to receiving the study drug.
  • Is taking or has taken over the counter (OTC) doses of 5-hydroxytrptophan or St John's Wort within 28 days prior to receiving the study drug.
  • Donation of blood or plasma of >400 mL within 1 month prior to first dosing until 4 weeks after final dosing.
  • Is pregnant, breastfeeding or planning to conceive.
  • Known difficulty with obtaining intravenous access.
  • Other eligibility considerations (i.e., participant personal circumstances, behavior, and/or any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to the study drug), as judged by the Investigator.

Additional Exclusion Criteria - Healthy Volunteers Only:

  • Current or previously diagnosed with a mental health disorder as defined by DSM-V criteria.
  • Use of any prescription medicine (except for hormonal contraceptives, if applicable), certain herbal supplements (to be reviewed by the Investigator), or OTC medicine during the 28 days before dosing.

Additional Exclusion Criteria - MDD Participants Only:

  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments given at an adequate dose for an adequate duration.
  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, an antipsychotic or a mood stabilizer.
  • Use of a prescription medicine (except participants may take a stable chronic dose of antidepressant medication(s) and/or sedatives/hypnotics, and may take hormonal contraceptives, if applicable), certain herbal supplements (to be reviewed by the Investigator), or OTC medicine during the 28 days before dosing (some exceptions apply).

Treatment and study plan

CYB003

Drug

CYB003 is a synthetic psilocybin analog.

Psychotherapy

Behavioral

Manualized psychotherapy (called EMBARK) performed by facilitators

Placebo

Drug

Placebo

psychological support

Behavioral

Manualized psychological support performed by facilitators

Primary outcomes

  1. Adverse Events (All Arms)

    Time frame: Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E)

    Any untoward medical occurrence in a clinical investigation participant administered a drug and does not necessarily have a causal relationship with the treatment

  2. Resting 12 Lead ECG ventricular rate (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23

    ventricular rate (beats per minute)

  3. Resting 12 Lead ECG ventricular rate (Arms C & D)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

    ventricular rate (beats per minute)

  4. Resting 12 Lead ECG ventricular rate (Arms E)

    Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

    ventricular rate (beats per minute)

  5. Resting 12 Lead ECG PR interval (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

    PR interval (milliseconds)

  6. Resting 12 Lead ECG PR interval (Arms C & D)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

    PR interval (milliseconds)

  7. Resting 12 Lead ECG PR interval (Arms E)

    Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

    PR interval (milliseconds)

  8. Resting 12 Lead ECG QRS duration (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

    QRS duration (milliseconds)

  9. Resting 12 Lead ECG QRS duration (Arms C & D)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

    QRS duration (milliseconds)

  10. Resting 12 Lead ECG QRS duration (Arms E)

    Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

    QRS duration (milliseconds)

  11. Resting 12 Lead ECG QT interval (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

    QT interval (milliseconds)

  12. Resting 12 Lead ECG QT interval (Arms C & D)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

    QT interval (milliseconds)

  13. Resting 12 Lead ECG QT interval (Arms E)

    Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

    QT interval (milliseconds)

  14. Resting 12 Lead ECG QTcF (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

    Corrected QT interval by Fredericia (milliseconds)

  15. Resting 12 Lead ECG QTcF (Arms C & D)

    Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

    Corrected QT interval by Fredericia (milliseconds)

  16. Resting 12 Lead ECG QTcF (Arms E)

    Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

    Corrected QT interval by Fredericia (milliseconds)

  17. Holter monitoring (Arms A & B)

    Time frame: Day -1, Day 1, Day 22

    Record of the electrical activity of the heart (Hz)

  18. Holter monitoring (Arms C & D)

    Time frame: Day -1, Day 1, Day 8

    Record of the electrical activity of the heart (Hz)

  19. Holter monitoring (Arm E)

    Time frame: Day -1, Day 1, Day 8, Day 15

    Record of the electrical activity of the heart (Hz)

  20. Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms)

    Time frame: Screening

    Evaluation tool that evaluates a lifetime history of suicidal ideation and/or behavior. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

  21. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B)

    Time frame: Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56

    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

  22. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D)

    Time frame: Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28

    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

  23. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E)

    Time frame: Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35

    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Secondary outcomes

  1. Mystical Experience Questionnaire (MEQ30) (Arms A & B)

    Time frame: Day 1 & Day 22

    The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. Each item is rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.

  2. Mystical Experience Questionnaire (MEQ30) (Arms C & D)

    Time frame: Day 1 & Day 8

    The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.

  3. Mystical Experience Questionnaire (MEQ30) (Arms C & D)

    Time frame: Day 1, Day 8, & Day 15

    The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.

  4. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms A & B)

    Time frame: Day 1 & Day 22

    The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.

  5. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms C & D)

    Time frame: Day 1 & Day 8

    The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.

  6. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arm E)

    Time frame: Day 1, Day 8, & Day 15

    The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.

  7. Hallucinogen Rating Scale (HRS) (Arms A & B)

    Time frame: Day 1 & Day 22

    The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.

  8. Hallucinogen Rating Scale (HRS) (Arms C & D)

    Time frame: Day 1 & Day 8

    The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.

  9. Hallucinogen Rating Scale (HRS) (Arm E)

    Time frame: Day 1, Day 8, & Day 15

    The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.

  10. Persisting Effects Questionnaire (PEQ) (Arms A & B)

    Time frame: Day 1 & Day 22

    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.

  11. Persisting Effects Questionnaire (PEQ) (Arms C & D)

    Time frame: Day 1 & Day 8

    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.

  12. Persisting Effects Questionnaire (PEQ) (Arm E)

    Time frame: Day 1, Day 8, & Day 15

    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.

  13. VAS Ratings of "Any Drug Effect" (Arms A & B)

    Time frame: Day 1 & Day 22

    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.

  14. VAS Ratings of "Any Drug Effect" (Arms C & D)

    Time frame: Day 1 & Day 8

    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.

  15. VAS Ratings of "Any Drug Effect" (Arm E)

    Time frame: Day 1, Day 8, & Day 15

    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.

  16. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from screening (Arms A & B)

    Time frame: Screening, Day -1, Day 1, Day 10, Day 17, Day 31, & Day 38

    The minimum and maximum values are 0 and 60 with a higher score indicating a worse outcome.

  17. Pharmacokinetic parameter of psilocin (Cmax) (Arms A & B)

    Time frame: Day 1, Day 2, Day 22, & Day 23

    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.

  18. Pharmacokinetic parameter of psilocin (Cmax) (Arms C & D)

    Time frame: Day 1, Day 2, Day 8, & Day 9

    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.

  19. Pharmacokinetic parameter of psilocin (Cmax) (Arm E)

    Time frame: Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16

    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.

  20. Pharmacokinetic parameter of psilocin (AUC) (Arms A & B)

    Time frame: Day 1, Day 2, Day 22, & Day 23

    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.

  21. Pharmacokinetic parameter of psilocin (AUC) (Arms C & D)

    Time frame: Day 1, Day 2, Day 8, & Day 9

    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.

  22. Pharmacokinetic parameter of psilocin (AUC) (Arm E)

    Time frame: Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16

    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.

Sponsors and collaborators

Lead sponsor

Cybin IRL Limited

Industry

Collaborators

  • Clinilabs Drug Development Corporation
  • Drug Safety Navigator

Registry information

Official study title

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
May 23, 2022
Registry last updated
Mar 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.